Brisbane-based Freenome has locked in a second major partnership for its blood-based cancer screening test, this time with a ...

Analysts said the deal shows Roche’s long-term strategy for its sequencing technology is “a clinical box for running NGS kits ...

The partnership will expedite the availability of Freenome's tests in markets outside the U.S, according to the company.

Freenome has announced a strategic agreement with Roche aimed at commercialising its cancer screening technology outside the ...

Freenome, an early cancer detection company developing blood-based screening tests, today announced a strategic collaboration agreement with Roche to commercialize Freenome's cancer screening ...

Roche will receive rights to at least 1 billion lateral flow tests annually from Sapphiros as well as access to the company's future molecular testing technology.

Illumina, Inc. (ILMN) 7th Annual Wolfe Research Healthcare Conference November 19, 2025 9:20 AM ESTCompany ParticipantsJacob Thaysen - CEO ...